What is ZYME's 12-month stock price target?

Zymeworks Inc. (ZYME) carries a 12-month consensus base price target of $27.58 (-3.6% from $28.61), with a bull-case target of $32.91 and a bear-case floor of $21.51.

Stock Ratings / Health Care / ZYME / forecast

MRVI (37) SDGR (53) SEPN (63) SRPT (27) ⌘ Pro Terminal →

Zymeworks Inc. (ZYME) 12-Month Stock Forecast & Price Target Cone

Q: Is ZYME stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates ZYME D (Sell — SELL) with an RQD Confidence score of 50/100.

$28.61 -0.35% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $28.54

Zymeworks Inc. (ZYME) carries a Roarable Rating of D (Sell) with 50/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 50/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.4% avg 90D alpha vs SPY) →

ROARABLE D • SELL / AVOID Cap $2.02B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ZYME Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ZYME stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Zymeworks Inc. (NASDAQ: ZYME) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $28.61 (-0.35% 1D, market cap $2.02B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ZYME ranks #260 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ZYME compare to MRVI and SDGR in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ZYME carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -32.2%. By comparison, MRVI (Maravai LifeSciences Holdings Inc. (Class A)) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $2.03B) and SDGR (Schrodinger Inc.) posts a D+ grade (53/100 RQD, P/E N/A, ROIC -35.0%, cap $2.03B). Among the 5-stock peer group, ZYME leads on earnings multiple (N/A) while SEPN leads on capital efficiency (-20.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ZYME?

▼

Per ZYME's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001937653), Zymeworks Inc. generated $106.0M in revenue (+38.9% YoY), -$81.1M in net income, and -$34.5M in free cash flow against $346.5M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $28.54 (-0.25%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 50/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.4% avg 90D alpha vs SPY • 49.3% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-3.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ZYME)Realized 20D OHLCV Swing Band: ±7.9%

Deterministic 5-Pillar Attribution (50/100 Composite)

🔍 WHY ZYME SCORES 50/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+16/20 pts (32% of score)

20D Institutional Volume Accumulation (±7.9% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (28% of score)

Altman Z-Score 11.85 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$25.07+7.3% Next Q

Q2 (-2Q)

Grade D$26.91+7.2% Next Q

Q3 (-1Q)

Grade D$28.85-0.8% Next Q

Current

Grade D$28.61-1.4% Hist 90D α

Trajectory: D (42) → D (50)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ZYME Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ZYME currently carries a cautious 50/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($27.30) and Max Pain ($30.04) forces dealer call-delta covering toward $32.91.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ZYME• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ZYME Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 50%NO 50%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your ZYME Position Size: $10,000

Shares at $28.61: 349.5 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $21.51

$7,518

$-2,482 (-24.8%)

12M Consensus BaseTarget $27.58

$9,640

$-360 (-3.6%)

12M Bull Case BreakoutTarget $32.91

$11,503

+$1,503 (+15.0%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (32 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 6

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$29	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$31	69%	B
JP MorganUS Large-Cap Research	SELL	$25	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ZYME)

✓Walkthrough of ZYME's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ZYME // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +6.83%⚡ TESTING RESISTANCE

2026-11-03O $28.71H $28.71L $28.61C $28.61VOL 2.88M

RES: $29.36SUP: $25.45SMA50: $27.30SMA200: $25.27

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ZYME Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ZYME Butterfly Map → + Track ZYME →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +38.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ZYME today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ZYME. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ZYME today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ZYME)

Health Care Rank #260 of 1016 ⚔️ MRVI vs ZYME Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ZYME vs. MRVI, SDGR, SEPN, SRPT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Zymeworks Inc. (ZYME) ranks #260 by composite RQD confidence (50/100, grade D) and #254 by equity capitalization ($2.02B). Within this direct 5-issuer industry benchmark cohort, ZYME leads on earnings valuation at N/A trailing P/E, while SEPN leads on capital efficiency and profitability with -20.7% ROIC and — gross margin. SEPN currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with ZYME at 50/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ZYME ACTIVE Zymeworks Inc.	D	50/100	—	—	-32.2%	-0.35%	$2.02B	Benchmark Subject
MRVI Maravai LifeSciences Holdings Inc. (Class A)	D-	37/100	—	18.3%	-35.0%	-7.68%	$2.03B	/mrvi-vs-zyme →
SDGR Schrodinger Inc.	D+	53/100	—	55.7%	-35.0%	-9.50%	$2.03B	/sdgr-vs-zyme →
SEPN Septerna Inc.	C	63/100	—	—	-20.7%	-2.72%	$2.05B	/sepn-vs-zyme →
SRPT Sarepta Therapeutics Inc.	E	27/100	—	96.0%	-35.0%	-3.17%	$1.97B	/srpt-vs-zyme →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001937653

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Zymeworks Inc. (ZYME) reported GAAP revenue of $106.0M (+38.9% vs. FY2024 revenue of $76.3M , and +39.4% cumulative change since FY2023) , GAAP net income of -$81.1M, operating cash flow of -$33.0M, and free cash flow of -$34.5M (+69.2% YoY). On the balance sheet, ZYME closed FY2025 with $346.5M in total assets against $0 in total debt (Altman Z-Score: 11.85, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$106.0M	-$81.1M	-$33.0M	-$34.5M	$346.5M	—
FY2024 (FY)	2024-12-31	$76.3M	-$122.7M	-$110.1M	-$112.0M	$463.1M	—
FY2023 (FY)	2023-12-31	$76.0M	-$118.7M	-$118.3M	-$118.3M	—	—

3. ZYME Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ZYME stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ZYME compare to MRVI and SDGR in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ZYME?

Where is ZYME trading relative to its 50-day, 200-day, and 52-week technical levels?

ZYME last traded at $28.61 (-0.35% on volume of 2,880,120 shares), positioning the stock +4.80% above its 50-day simple moving average ($27.30) and +13.22% above its 200-day simple moving average ($25.27). Across its 52-week range of $16.00 to $31.34, ZYME sits at the 82.2% percentile with a 14-day RSI of 60.0 (BULLISH MOMENTUM) and an implied next-earnings move of ±7.9% ($26.35 to $30.87).

Direct Sub-Reports: ZYME RQD Cockpit ZYME 12M Forecast ZYME Earnings & Move ZYME Dividends & DRIP ZYME Insiders & 13F ZYME Whale Options ZYME Profit Sankey ZYME News & Why

ROARABLE RATING BRIEF • RQD 50/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ZYME — Zymeworks Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:26:58Z

1. Roarable Rating Brief: What This Means to a Prospective Investor

ZYME scores 49 out of 100, grade D, labeled "Roarable Sell — Underperform / Distribution Warning." The five pillars are:

Fundamental Cash Engine: 10 / 20. ROIC is -32.2% and FCF yield is -1.71%. For an investor, this means the business is not currently generating returns on invested capital or free cash flow; any upside case depends on future operating improvement rather than existing cash generation.
Whale 13F Flow: 15 / 20. this pillar reflects institutional accumulation and options positioning. It is the strongest pillar, suggesting some institutional interest, though the source data provides no holder detail to verify it (see Analyst View section).
Insider Conviction: 3 / 20. this reflects SEC Form 4 and Congressional PTR cluster flow. The low score indicates weak insider conviction signals in the data.
Macro Regime Fit: 7 / 20. beta is 1.0 with a sector sensitivity assessment. A beta of 1.0 means the stock is expected,.
Forensic Balance Sheet: 14 / 20. Altman Z is 11.85, Piotroski F is 4/9, and Debt/Equity is 0.5. The balance-sheet metrics are the most supportive pillar, indicating a relatively solid liquidity and solvency position even as operations lose money.

Taken together, a prospective investor should weigh the strong balance-sheet and institutional-interest pillars against the weak cash-generation and insider-conviction pillars. The valuation tradeoff is that without positive earnings or cash flow, traditional earnings multiples are unavailable, so price rests on expectations rather than reported profitability.

2. Business Model, Unit Margins & SEC Financial Trajectory

Zymeworks Inc. (ZYME) is listed on NASDAQ and classified under the Health Care sector, Biotechnology: Pharmaceutical Preparations industry..0B.

Revenue rose from $76.0M (FY 2023) to $106.0M (FY 2025), while operating losses narrowed from -$138.1M to -$92.5M over the same span. Per the market data, operating margin is -60%, net margin is -60%, and gross margin is 0%. ROIC is -32.2%, the Altman Z-Score is 11.85, and the Piotroski F-Score is 4/9. Debt/Equity is 0.5 per the RQD rating, and FY 2025 cash is $41.2M .

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case: Revenue grew from $76.0M to $106.0M while the Roarable RQD rating gives the balance sheet 14 of 20 points, with an Altman Z of 11.85. With Fundamental Cash Engine at 10/20 (ROIC -32.2%, FCF yield -1.71%) and Institutional Whale Flow at 16/20, sustained execution supports upside toward the top of the $16.00 – $31.34 52-week range.
🐻 Primary Bear Case: ROIC is -32.2% and FCF yield is -1.71%, and the Roarable RQD rating scores insider conviction at only 3 of 20. Investors must weigh current valuation against -60.0% operating margins and a 1.00 macro beta if sector demand softens.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

A prospective investor should note that the licensing and approval headlines imply partner-dependent economics, but the source does not map those dependencies.

Key Question #1: What is the scope and commercial timing of the FDA approval referenced in the news wire?
Key Question #2: What drove the FY 2025 revenue increase, and how much is recurring versus one-time licensing revenue?
Key Question #3: Why are EPS, debt, and forward valuation metrics unavailable, and how does the company fund its operating losses over time?

ZYME Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Zymeworks Inc. (ZYME) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ZYME Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance UK • 19h ago

Zymeworks Inc. (ZYME) stock price, news, quote and history

Yahoo Finance UK report covering Zymeworks Inc. (ZYME) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com • 22h ago

Zymeworks stock price target reaffirmed at $32 by Citizens

Investing.com report covering Zymeworks Inc. (ZYME) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 1d ago

Zymeworks stock surges on $813M Roche licensing deal

Yahoo Finance report covering Zymeworks Inc. (ZYME) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stocktwits • 1d ago

JAZZ, ONC, ZYME Stocks In Focus After FDA Approves Gastroesophageal Cancer Therapy

Stocktwits report covering Zymeworks Inc. (ZYME) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Truist Securities maintains Buy rating on Zymeworks, $35 price target

TradingView report covering Zymeworks Inc. (ZYME) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

ZW191 Trial Data Could Be A Big Test For Zymeworks Stock

Simply Wall St report covering Zymeworks Inc. (ZYME) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com • 1d ago

Why is Zymeworks stock surging today?

Investing.com report covering Zymeworks Inc. (ZYME) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Zymeworks Inc. (ZYME) - What Are Researchers Thinking About This Stock?

MarketBeat report covering Zymeworks Inc. (ZYME) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ZYME Bull vs. Bear Conversation Board — What's Your Call at $28.61?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ZYME 🐻 33% BEARISH CONVICTION

QU QuantViper Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $37.77 (+32.0%)

📌 Pinned Debate

Revenue grew from $76.0M to $106.0M while the Roarable RQD rating gives the balance sheet 14 of 20 points, with an Altman Z of 11.85.

Long ZYME at $28.61 targeting $37.77. Revenue grew from $76.0M to $106.0M while the Roarable RQD rating gives the balance sheet 14 of 20 points, with an Altman Z of 11.85.. Institutional whale score is 16/20 and the risk/reward vs. the $16.00 52-week low is skewed heavily in favor of bulls.

ArenaChamp_24 🐂 BULL

@MeanReversion_88 Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

ME MeanReversion_88 Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $24.32 (-15.0%)

Spot @ $28.61

ROIC is -32.2% and FCF yield is -1.71%, and the Roarable RQD rating scores insider conviction at only 3 of 20.

Fading this rally in ZYME at $28.61. ROIC is -32.2% and FCF yield is -1.71%, and the Roarable RQD rating scores insider conviction at only 3 of 20.. With a beta of 1.0 and the stock sitting at $28.61 (52-wk range $16.00–$31.34), the easy multiple expansion is already priced in.